Skip to main content

Want a detailed portfolio tracker?

OverviewPerformanceMetricsFinancialsIndustryCorrelations
Market CapEPSP/EP/SP/BSharesProfit MarginOperating MarginDebt to EquityRevenueEarningsEBITDAFree Cash FlowTotal DebtTotal AssetsROAROE

Bellevue Life Sciences Acquisition (OSRH) Operating Margin (2024 - 2026)

Bellevue Life Sciences Acquisition (OSRH) operating margin from Mar 31, 2024 to Mar 31, 2026. The current Bellevue Life Sciences Acquisition (OSRH) operating margin is -764.58%. You can export chart.

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Annual Operating Margin

Quarterly Operating Margin

Annual Operating Margin change of Bellevue Life Sciences Acquisition (OSRH)

YearOperating MarginChange
2025-630.24%
+90.31%
2024-331.16%
N/A

Comparison Bellevue Life Sciences Acquisition (OSRH) operating margin with competitors

Bellevue Life Sciences Acquisition (OSRH) operating margin is -764.58%.

TickerNameOperating MarginUpside
VIRVir Biotechnology Inc459241.00%-60164.22%
APLMApollomics Inc - Class A431.90%-156.49%
ABUSArbutus Biopharma Corp94.30%-112.33%
SAVACassava Sciences Inc.93.36%-112.21%
RPRXRoyalty Pharma plc - Class A89.29%-111.68%
GLPGGalapagos NV84.24%-111.02%
NEUPNeuphoria Therapeutics Inc79.85%-110.44%
BDTXBlack Diamond Therapeutics Inc77.90%-110.19%
CTNMContineum Therapeutics Inc - Class A77.87%-110.18%
CVACCureVac N.V.74.59%-109.76%
IPSCCentury Therapeutics Inc67.95%-108.89%
FULCFulcrum Therapeutics Inc65.62%-108.58%
AVIRAtea Pharmaceuticals Inc63.06%-108.25%
PLXProtalix BioTherapeutics Inc62.65%-108.19%
PRTAProthena Corporation plc58.80%-107.69%
AUPHAurinia Pharmaceuticals Inc53.31%-106.97%
ADMAAdma Biologics Inc50.90%-106.66%
RPTXRepare Therapeutics Inc50.85%-106.65%
CRMDCorMedix Inc49.96%-106.53%
HCWBHCW Biologics Inc49.78%-106.51%
CPRXCatalyst Pharmaceuticals Inc49.02%-106.41%
SRPTSarepta Therapeutics Inc49.00%-106.41%
HALOHalozyme Therapeutics Inc48.98%-106.41%
KRYSKrystal Biotech Inc46.14%-106.03%
AGENAgenus Inc44.62%-105.84%
CGENCompugen Ltd43.05%-105.63%
SVASinovac Biotech Ltd42.30%-105.53%
EXELExelixis Inc41.15%-105.38%
QTTBQ32 Bio Inc39.80%-105.21%
INVAInnoviva Inc38.94%-105.09%
VRTXVertex Pharmaceuticals Inc38.10%-104.98%
NXTCNextcure Inc36.70%-104.80%
LGNDLigand Pharmaceuticals Inc - Class B33.58%-104.39%
SLNOSoleno Therapeutics Inc33.06%-104.32%
JAZZJazz Pharmaceuticals plc31.49%-104.12%
ARGXArgen X SE30.35%-103.97%
CAICaris Life Sciences Inc - Class A30.19%-103.95%
TNGXTango Therapeutics Inc26.15%-103.42%
GMABGenmab25.11%-103.28%
ZVRAZevra Therapeutics Inc24.40%-103.19%
TECHBio-Techne Corp24.24%-103.17%
INCYIncyte Corp23.66%-103.09%
RIGLRigel Pharmaceuticals20.21%-102.64%
ICCCImmucell Corp19.01%-102.49%
REGNRegeneron Pharmaceuticals Inc17.83%-102.33%
NERVMinerva Neurosciences Inc17.73%-102.32%
HRMYHarmony Biosciences Holdings Inc17.31%-102.26%
TGTXTG Therapeutics Inc16.98%-102.22%
BMRNBiomarin Pharmaceutical Inc16.92%-102.21%
ONCBeiGene Ltd16.51%-102.16%
PTCTPTC Therapeutics Inc16.50%-102.16%
ENVBEnveric Biosciences Inc13.38%-101.75%
VXRTVaxart Inc13.19%-101.73%
VRNAVerona Pharma Plc12.90%-101.69%
ALNYAlnylam Pharmaceuticals Inc12.01%-101.57%
ASNDAscendis Pharma A/S10.06%-101.32%
APLSApellis Pharmaceuticals Inc9.86%-101.29%
FOLDAmicus Therapeutics Inc8.61%-101.13%
CGEMCullinan Oncology Inc7.24%-100.95%
IMCRImmunocore Holdings plc6.82%-100.89%
NAGENiagen Bioscience Inc5.01%-100.66%
NUVBNuvation Bio Inc - Class A4.66%-100.61%
BMEABiomea Fusion Inc2.46%-100.32%
TLXTelix Pharmaceuticals Ltd1.58%-100.21%
HOTHHoth Therapeutics Inc0.17%-100.02%
BBLGBone Biologics Corp0.04%-100.01%